SEARCH

SEARCH BY CITATION

Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers

Sandra D. Comer, Maria A. Sullivan, Suzanne K. Vosburg, Jeanne Manubay, Leslie Amass, Ziva D. Cooper, Phillip Saccone & Herbert D. Kleber

In the Declarations of interest section of this paper [1], Purdue Pharmaceuticals was listed incorrectly. The company name should have been Purdue Pharma L.P.

We apologise for this error

Reference

  1. Top of page
  2. Reference
  • 1
    Comer S. D., Sullivan M. A. Vosburg S. K., Manubay J., Amass L., Cooper Z. D., Saccone P., Kleber H. D. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction 2009; 105: 70918.